XEGLYZE Drug Patent Profile

✉ Email this page to a colleague

When do Xeglyze patents expire, and what generic alternatives are available?

Xeglyze is a drug marketed by Hatchtech and is included in one NDA. There are five patents protecting this drug.

This drug has thirty-six patent family members in fifteen countries.

The generic ingredient in XEGLYZE is abametapir. One supplier is listed for this compound. Additional details are available on the abametapir profile page.

DrugPatentWatch^® Generic Entry Outlook for Xeglyze

Xeglyze was eligible for patent challenges on July 31, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 17, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for XEGLYZE?
What are the global sales for XEGLYZE?
What is Average Wholesale Price for XEGLYZE?

Summary for XEGLYZE

International Patents:	36
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	112
Patent Applications:	283
What excipients (inactive ingredients) are in XEGLYZE?	XEGLYZE excipients list
DailyMed Link:	XEGLYZE at DailyMed

Drug patent expirations by year for XEGLYZE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XEGLYZE

Generic Entry Date for XEGLYZE^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up NDA: 206966 Dosage: LOTION;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for XEGLYZE

XEGLYZE is protected by five US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of XEGLYZE is ⤷ Sign Up.

This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting XEGLYZE

Pediculicidal composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER

Methods and compositions for controlling ectoparasites
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER

Methods and compositions for controlling ectoparasites
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

FDA Regulatory Exclusivity protecting XEGLYZE

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hatchtech	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Hatchtech	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Hatchtech	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Hatchtech	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for XEGLYZE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hatchtech	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020	⤷ Sign Up	⤷ Sign Up
Hatchtech	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020	⤷ Sign Up	⤷ Sign Up
Hatchtech	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for XEGLYZE

When does loss-of-exclusivity occur for XEGLYZE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 14377875
Patent: Pediculicidal composition
Estimated Expiration: ⤷ Sign Up

Canada

Patent: 33081
Patent: COMPOSITION PEDICULICIDE (PEDICULICIDAL COMPOSITION)
Estimated Expiration: ⤷ Sign Up

Eurasian Patent Organization

Patent: 1732
Patent: ПЕДИКУЛИЦИДНАЯ КОМПОЗИЦИЯ (PEDICULICIDAL COMPOSITION)
Estimated Expiration: ⤷ Sign Up

Patent: 1691033
Patent: ПЕДИКУЛИЦИДНАЯ КОМПОЗИЦИЯ
Estimated Expiration: ⤷ Sign Up

European Patent Office

Patent: 82424
Patent: COMPOSITION PEDICULICIDE (PEDICULICIDAL COMPOSITION)
Estimated Expiration: ⤷ Sign Up

Japan

Patent: 11751
Estimated Expiration: ⤷ Sign Up

Patent: 17500342
Patent: シラミ駆除組成物
Estimated Expiration: ⤷ Sign Up

New Zealand

Patent: 0995
Patent: Pediculicidal composition
Estimated Expiration: ⤷ Sign Up

Spain

Patent: 67618
Estimated Expiration: ⤷ Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XEGLYZE around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Portugal	2457582		⤷ Sign Up
New Zealand	720995	Pediculicidal composition	⤷ Sign Up
Hong Kong	1169045	用於控制體外寄生蟲的方法和組合物 (METHOD AND COMPOSITIONS FOR CONTROLLING ECTOPARASITES)	⤷ Sign Up
China	100593419		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration